Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100020/S066

cobas HPV

Roche Molecular Systems, Inc. · Decision date Oct 27, 2026

MEDTECHLEDGER EXPLANATIONP100020/S066

What did the FDA decide?

This record documents a 30-Day Notice supplement (S066) to PMA P100020 for cobas® HPV, a human papillomavirus DNA detection kit (product code MAQ, microbiology). The stated purpose is "to change the manufacturing process for oligonucleotides," filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The notice concerns how oligonucleotide components are manufactured; the supplied fields do not specify which oligonucleotides, what the prior or revised process steps are, or what validation data support the change.

The identifier establishes this as a supplement to the existing P100020 approval, not a new approval of the whole system, and the notice is not an original PMA. Roche Molecular Systems, Inc. is the applicant, and the decision field reads OK30. That the notice reports a manufacturing process change does not by itself demonstrate safety or clinical effectiveness; the source fields contain no such findings.

FDA approval order statement

to change the manufacturing process for oligonucleotides
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Microbiology
Decision date
Oct 27, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P100020/S066
Regulatory pathway
PMA supplement
Product code
MAQ
Decision code
OK30
Decision date
Oct 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.

Product code
MAQ
FDA device class
3

For the original device and its historical approval scope, see PMA P100020. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P100020/S066 received

    Application receipt date recorded by FDA.

  2. P100020/S066 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P100020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100020

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA approvalApr 19, 2011FDA

Explore the linked device profile

Other records with product code MAQ

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HPVP190028/S026
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Alinity m HR HPVP230003/S019
Abbott Molecular, Inc.PMA supplementSep 2, 2026FDA
Abbott Molecular, Inc.PMA approvalNov 1, 2023FDA
Roche Molecular Systems, Inc.PMA approvalApr 3, 2020FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular Systems, Inc.

Headquarters
Not reported
Brand website
roche.com
FDA applicant address
4300 Hacienda Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records